Q3 FY2026 · ended Sep 30, 2026 · Revenue $33.55M, +14.0% YoY · Filed Nov 4, 2026
Alamar Biosciences, Inc. (ALMR) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $33.5 million and a net loss of $13.3 million. Free cash flow was -$15.2 million. As of Sep 30, 2026 it held $226.6 million in cash and investments and $42.4 million in total debt.
Revenue
$33.55M
+14.0% vs prior quarter
Net income
$-13.34M
-1.1% vs prior quarter
Operating cash flow
$-14.73M
-30.1% vs prior quarter
Free cash flow
$-15.20M
-1.5% vs prior quarter
EPS
$-0.19
+13.6% vs prior quarter
Dividend per share
None
Shares outstanding
69.48M
+0.1% vs prior quarter
Net cash
$184.24M
Q3 FY2026
Operating margin
-45.1%
Q3 FY2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- ALMR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fremont, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2104204
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|---|
| Revenue | $33.5M | $29.4M | $26.0M |
| Operating income | -$15.1M | -$13.5M | -$12.3M |
| Net income | -$13.3M | -$13.2M | -$21.3M |
| Diluted EPS | -$0.19 | -$0.22 | -$1.74 |
| Operating cash flow | -$14.7M | -$11.3M | -$20.3M |
| Free cash flow | -$15.2M | -$15.0M | -$20.9M |
| Total assets | $378.0M | $391.0M | $186.5M |
| Total liabilities | $74.3M | $78.1M | $129.5M |
| Stockholders' equity | $303.7M | $312.9M | -$178.1M |
| Cash and investments | $226.6M | $250.1M | $64.6M |
| Total debt | $42.4M | $41.5M | $30.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 3, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 1, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 15, 2026 |
All 63 Alamar Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.